Funder
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
BrightFocus Health Research Board Ireland (Grant RP/2008/30)
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference71 articles.
1. Liu, J., Yang, B., Ke, J., Li, W. & Suen, W. C. Antibody-based drugs and approaches against amyloid-beta species for Alzheimer’s disease immunotherapy. Drugs Aging 33, 685–697 (2016).
2. Golde, T. E. Open questions for Alzheimer’s disease immunotherapy. Alzheimer’s Res. Ther. 6, 3 (2014).
3. van Dyck, C. H. Anti-amyloid-beta monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol. Psychiatry 83, 311–319 (2017).
4. Kohyama, K. & Matsumoto, Y. Alzheimer’s disease and immunotherapy: what is wrong with clinical trials? Immunotargets Ther. 4, 27–34 (2015).
5. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献